BIOA.F Stock Overview
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bioasis Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.006 |
| 52 Week High | CA$0.018 |
| 52 Week Low | CA$0.0015 |
| Beta | 0.46 |
| 1 Month Change | -14.29% |
| 3 Month Change | 46.34% |
| 1 Year Change | -57.30% |
| 3 Year Change | -97.76% |
| 5 Year Change | -97.65% |
| Change since IPO | -99.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOA.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -28.1% | -3.9% | -3.1% |
| 1Y | -57.3% | -1.8% | 20.9% |
Return vs Industry: BIOA.F underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: BIOA.F underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| BIOA.F volatility | |
|---|---|
| BIOA.F Average Weekly Movement | 60.7% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOA.F's share price has been volatile over the past 3 months.
Volatility Over Time: BIOA.F's weekly volatility has decreased from 80% to 61% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Deborah Rathjen | www.bioasis.us |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company’s in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007).
Bioasis Technologies Inc. Fundamentals Summary
| BIOA.F fundamental statistics | |
|---|---|
| Market cap | US$287.19k |
| Earnings (TTM) | -US$2.08m |
| Revenue (TTM) | US$194.83k |
1.5x
P/S Ratio-0.1x
P/E RatioIs BIOA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA.F income statement (TTM) | |
|---|---|
| Revenue | CA$269.38k |
| Cost of Revenue | CA$968.85k |
| Gross Profit | -CA$699.47k |
| Other Expenses | CA$2.18m |
| Earnings | -CA$2.88m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.036 |
| Gross Margin | -259.66% |
| Net Profit Margin | -1,067.59% |
| Debt/Equity Ratio | -82.1% |
How did BIOA.F perform over the long term?
See historical performance and comparison